echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > [quick news] on Thursday, March 22, 2018, scientists developed the male contraceptive pill: will men take it?

    [quick news] on Thursday, March 22, 2018, scientists developed the male contraceptive pill: will men take it?

    • Last Update: 2018-03-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Scientists develop male contraceptives: can men take them? Women's birth control pills came out in 1961, but scientists began to study men's birth control pills nearly 30 years ago According to the daily mail of the UK, the research team of the University of Washington has proved in the clinical trials of male contraceptives that the drug must be taken together with food, which can block the receptors in the brain to block the hormones needed for sperm production After one month of taking the drug, the testosterone and gonadotropin of male significantly decreased, and will not cause damage to the liver and kidney Professor Ying Guangguo of South China Normal University is a new member of the editorial board of Environmental Science: Processes & impacts Recently, Professor Ying Guangguo, Dean of the Environmental Research Institute of South China Normal University, was announced as a member of the editorial board of the journal by the Royal chemical society At the same time, Professor Ying Guangguo will also be the special editor of the journal emerging investigators series The rumor about the acquisition of RSC Broadcom keeps guessing After the failure of the acquisition of Qualcomm by the president of the United States, Broadcom has been named Recently, the market continues to spread Broadcom has begun to look for other acquisition targets Besides the recently released xlinix, according to the motley pool, the financial information website of the United States It's another revelation Among the three targets targeted by Broadcom, MediaTek is one of them The motley pool ADC Combination therapy has been approved by FDA Recently, the first-line treatment of advanced lymphoma has been announced by the US FDA to approve the expanded indications of antibody drug coupling agent adcetris (brentuximab vedotin) of Seattle genetics, which is used together with chemotherapy to treat the treated patients with stage III or stage IV classic Hodgkin's lymphoma Adcetris is expected to bring good news to lymphoma patients FDA food and Drug Administration urges pidomode enterprise to start clinical effectiveness test as soon as possible On March 20, the State Food and Drug Administration issued two notices on the pediatric drug "pidomode" which had been questioned before, asking Puli Chemical Industry Co., Ltd of Switzerland to start the clinical effectiveness test as soon as possible, and six local food and drug administration to urge the production enterprises of pidomode preparation in the administrative region to start the clinical effectiveness test as soon as possible The evaluation results shall be reported to the drug evaluation center of the State Food and drug administration within 3 years CFDA
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.